TAMPA, Florida, May 20, 2013 /PRNewswire/ --
Elsevier will provide Apex with essential drug information in a streamlined database solution
Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced an agreement with Apex Affinity, provider of innovative prescription discount programs for uninsured and underinsured families nationwide. Apex has selected Elsevier's Gold Standard Drug Database for providing current and accurate drug content to enhance its member products, including a new consumer drug reference portal.
Apex leverages the purchasing power of millions of consumers to negotiate deep discounts on brand-name and generic prescriptions at nearly all major big box stores, drug store chains and independent neighborhood pharmacies. Apex will use Elsevier's Gold Standard Drug Database to enable members to compare drug pricing, look-up accurate dosage information, and learn about alternative therapies and what a medication is used for and what it does."With the Gold Standard Drug Database, we can provide our members with the most up-to-date drug information in an easy to use format," said Scott Paul, Apex's Chief Executive Officer. "It will help our members make informed decisions about their medications and their health." The Gold Standard Drug Database content is updated daily and has a peer-reviewed editorial process in place to ensure the highest accuracy of drug product information, drug pricing and patient education information. Apex will benefit from the database's modern technical architecture and flexible implementation, which distinguishes Gold Standard Drug Database from other drug databases. "With the implementation of our Gold Standard Drug Database, Apex will have the confidence that their value-added consumer reference products contain superior drug information that allows their members to swiftly and effortlessly research their medications," said Trygve Anderson, R.Ph. Vice President of Product Management, Elsevier's Gold Standard.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV